Bulletin Board

Bulletin Board

Latest information for immunisation providers in Tasmania.

3 July 2018

Immunisation schedules

Changes to the National Immunisation Program schedule starting 1 July 2018

Resources for Vaccination Providers

18 December 2017

Immunisation update

24 July 2017

A free meningococcal W vaccination program will be offered in Tasmania for older teens aged 15 to 19 years during school term three of 2017.

Under the new program more than 33 000 15-19 year old Tasmanian teenagers will be eligible to receive a four-antigen vaccine, which will provide protection against meningococcal A, C, W and Y strains.

Meningococcal W

15 December 2016

Immunisation update

2 November 2016

Zostavax factsheet for providers

October 2016

Adult and Child Immunisation Schedule

Adult and Child Aboriginal and Torres Strait Islander Immunisation Schedule

22 August 2016

Immunisation update

31 March 2016

Pertussis booster for children aged 18 months

January 2016

Influenza Immunisation Schedule

01 December 2015

Hepatitis B Vaccination for High Risk Groups in Tasmania (November 2015)

08 May 2015

Free whooping cough vaccine for pregnant women

22 January 2015

Important Information about the 2015 Seasonal Influenza vaccine

30 September 2014

Recall of Meningitec® (Meningococcal serogroup C vaccine)

On 29 September 2014, Emerge Health in consultation with the Australian Government Department of Health Therapeutic Goods Administration (TGA)  voluntarily recalled all unexpired doses of Meningitec® vaccine, due to the potential for particulate contamination.

Emerge Health has advised that a review of batches manufactured since October 2012 found a small number of syringes had been contaminated with iron oxide (rust) and oxidised stainless steel, both of which originated from manufacturing equipment. The review was prompted by two European reports of particulate matter in the syringes.

At the time of this recall, neither TGA nor Emerge Health were aware of any product complaints from patients or healthcare providers that suggest vaccine doses supplied in Australia have been contaminated.

All batches supplied in Australia identify Pfizer as the sponsor of Meningitec®

Meningitec® is no longer used in the National Immunisation Program (NIP), apart from infrequent catch-up dosing of older children in some jurisdictions. Alternative products are available for this purpose.

Since July 2013, a combined Meningococcal serogroup C and Haemophilus influenza type b vaccine has replaced the use of Meningitec® at age 12 months.

Immunisation providers in Tasmania have been advised that if they hold any stocks of Meningitec® vaccine, to quarantine and not use it.

Immunisation providers are being contacted by Emerge Health to arrange collection of the recalled vaccine (both NIP-supplied Meningitec®, and any other purchased stock).

Questions about this recall can be directed to Emerge Health on 03 9077 4486, (business hours), fax 03 8672 0792 or email (medicalaffairs@emergehealth.com.au).

Further information about this recall can be found on the TGA website: http://www.tga.gov.au/safety/alerts-medicine-meningitec-meningococcal-140929.htm

21 August 2013

ATAGI clinical advice for immunisation providers on the use of Menitorix® in delivering catch-up vaccinations, July 2013


25 June 2013

Changes to the NIP for Priorix-Tetra® (MMRV) and Menitorix® (Hib/MenC)

Important information on changes to the National Immunisation Program Schedule for Priorix-Tetra® (MMRV) and Menitorix® (Hib/MenC)

11 October 2012

The Prevenar 13® Supplementary Dose Program has now finished

This free program provided a dose of Prevenar 13® pneumococcal vaccine to children aged 12 -35 months who had completed a primary course of Prevenar 7®, but who were still young enough to be at increased risk of invasive pneumococcal disease. The supplementary dose program started on 1 October 2011 and stopped on 30 September 2012.
All infants now routinely receive a 3-dose course of Prevenar 13® pneumococcal vaccine.
Children with predisposing medical conditions should receive another dose of Prevenar 13® at age 12 months, and a dose of the polysaccharide vaccine, Pneumovax23®, at age three to four years.

Immunisation Schedules

Adult and Child Immunisation Schedule

Adult and Child Aboriginal and Torres Strait Islander Immunisation Schedule

Influenza Immunisation Schedule

27 February 2013

Childhood Immunisation Schedule

Due to the increase of pertussis in the community it is still recommended that the first doses of vaccines (usually scheduled at two months) can be brought forward to six weeks. The timing of subsequent doses can be continued from four months of age as per the Immunisation Schedule for Children in Tasmania 2012.

18 August 2011

Ongoing HPV vaccination program

Gardasil® is now scheduled for girls aged 12 or 13 years in either grade 6 or 7 as part of a school-based vaccination program. General Practitioners may also offer Gardasil® to girls who miss out at school or for those who prefer to attend a General Practice. Gardasil® vaccine is funded for all girls aged 12-16 years who have not already received three doses. Providers can place orders for Gardasil® with CDPU as per the usual ordering process for funded vaccines.

More information

Call the Public Health Hotline - Tasmania on 1800 671 738

September 2018